Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 13/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190947 | 1.00 | GPR183 (0.48) | GPR183TDP1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL14218062 | 0.89 | GPR183 (0.61) | GPR183TDP1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL4378984 | 0.87 | GPR183 (0.55) | GPR183TDP1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL14190909 | 0.87 | GPR183 (0.55) | GPR183TDP1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL13636370 | 0.82 | GPR183 (0.48) | GPR183SMN1; SMN2 | |
| SCHEMBL4381584 | 0.80 | SMN1; SMN2 (0.47) | GPR183TDP1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL13636007 | 0.80 | SMN1; SMN2 (0.47) | GPR183TDP1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL4381901 | 0.80 | SMN1; SMN2 (0.46) | GPR183HPGDTSHRSMN1; SMN2AR | |
| SCHEMBL4380528 | 0.80 | ALDH1A1 (0.48) | GPR183HPGDTSHRSMN1; SMN2AR | |
| SCHEMBL13636356 | 0.80 | ALDH1A1 (0.48) | GPR183HPGDTSHRSMN1; SMN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | GPR183 264/4885TDP1 3908/4885HPGD 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.